Membrane fatty acids, niacin flushing and clinical parameters

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 9-15

  Glen, A I M ^a   Cooper, S J ^b   Rybakowski, J ^c   Vaddadi, K ^d   Brayshaw, N ^e   Horrobin, D F ^f  

^a Craig Dunain Hospital   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^d MAROONDAH HOSPITAL   (Australia)

^e Scotia Pharmaceuticals Ltd   (United Kingdom)

^f Scotia Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CLOZAPINE; DOCOSAHEXAENOIC ACID; NICOTINIC ACID; PRIMROSE OIL;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOCHEMISTRY; DIET; ERYTHROCYTE MEMBRANE; EVALUATION AND FOLLOW UP; FATTY ACID METABOLISM; FEMALE; FLUSHING; GAS LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TECHNIQUE;

PRIMULA;

EID: 0029743510     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90139-8     Document Type: Conference Paper

References (33)

1. Glen A. I. T., Glen E. M. T., Horrobin D. F. et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
2. Sevy S., Davidson M. The costs of cognitive impairment in schizophrenia. Schizophr Res 1995; 17: 1-3.
3. Glen A. I. M., Ongley G. C., Robinson K. Diminished membrane transport in manic-depressive psychosis and recurrent depression. Lancet 1968; ii: 241-243.
4. Glen A. I. M., Ongley G. C., Robinson K. Effect of a sensory stimulus on an impaired membrane transport system in man. Nature 1969; 221: 565-566.
5. Glen A. I. M. Lithium prophylaxis of recurrent affective disorders. J Affect Disor 1985; 8: 259-265.
6. Horrobin D. F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; I: 936-937
7. Marchbanks R. M., Mulcrone J., Whatley S. A. Aspects of oxidative metabolism in schizophrenia. Br J Psychiat 1995; 167: 293-298.
8. Devane W. A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
9. Di Marzo V., Fontana A., Cadas H. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-691.
10. McGuire P. K., Jones P., Harvey I. et al. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15: 277-281.
11. Horrobin D. F. Schizophrenia: a biochemical disorder. Biomedicine 1980; 32: 54-55.
12. Eklund B., Kaiser L., Nowak J., Wenmalm A. Prostaglandins contribute to the vasodilatation induced by nicotinic acid. Prostaglandins 1979; 17: 821-838.
13. Miller D. R., Hayes K. C. Niacin. In: Hathcock J., ed. Nutritional Toxicology. Vol. 1. New York Academic Press, 1982: 108.
14. Morrow J. D., Awad J. A., Oates J. A., Roberts L. J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812-815.
15. Lewis R. A., Soter N. A., Diamond P. T. et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982; 129: 1627-1631.
16. Wilkin J. K., Fortner G., Reinhart L. A. et al. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther 1985; 38: 273-277.
17. Plummer N. A., Hensby C. N., Kobza Black A., Greaves M. N. Prostaglandin activity in sustained inflammation of human skin before and after aspirin. Clin Sci Mol Med 1977; 52: 615-620.
18. Urade Y., Ujihara M., Hariguchi Y. et al. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. J Immunol 1989; 143: 2982-2987
19. Balsinde J., Bianco I. D., Ackermann E. J. et al. Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 1995; 92: 8527-8531.
20. Ban T. A. Canadian niacin study. Schizophr Bull 1971; 4: 6-7.
21. Abdulla Y. H., Hamadah K. Effects of ADP on PGE formation in blood platelets from patients with depression, mania, and schizophrenia. Br J Psychiatr 1975; 127: 591-595.
22. Rotrosen J., Miller A. D., Mandio D. et al. Reduced PGE-stimulated 3H-cAMP accumulation in platelets from schizophrenics. Life Sci 1978; 23: 1989-1996.
23. Wilson D. W. S., Douglass A. B. Niacin skin test is not diagnostic of schizophrenia. Biol Psychiatr 1986; 21: 974-977
24. Fiedler F., Wolkin A., Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol Psychiatr 1986; 21: 1347-1350.
25. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol Psychiatr 1991; 29: 834-836.
26. Foster P. Neuroleptic equivalence. Pharmaceut J 1989; 431-432.
27. McGuffin P., Farmer A. E., Gottesman I. I. et al. Twin concordance for operationally defined schizophrenia: confirmation of familiality and heritability. Arch Gen Psychiatr 1984; 41: 541-545.
28. Manku M. S., Horrobin D. F., Morse N. et al. Reduced levels of prostaglandin precursors in the blood of atopic patients. Prostaglandins Leukot Essent Fatty Acids 1982; 9: 615-628.
29. Overall J. E., Gorham D. R. The Brief Psychiatric Rating Scale. Psychol Reports 1962; 10: 799-812.
30. Andreasen N. C., Olsen S. Negative v. positive schizophrenia: definition and validation. Arch Gen Psych 1982; 39: 789-794.
31. Honigfeld G., Klett C. J. The Nurse's Observation Scale for Inpatient Evaluation: a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965; 21: 65-71.
32. Montgomery S. A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatr 1979; 134: 382-389.
33. Trzeciak H. I., Kalacinski W., Malecki A., Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur Arch Psychiatr Clin Neurosci 1995; 245: 179-182.